Interferon alfa (IFN-␣) is currently the only well-established therapy for viral hepatitis. However, its effectiveness is much reduced (<10%) in alcoholic patients. The mechanism underlying this resistance is not fully understood. In this study, we examined the expression of IFN-␣ signaling components and its inhibitory factors in 9 alcoholic liver disease (ALD) and 8 healthy control liver tissues. In comparison with normal control livers, expression of IFN-, IFN-␣ receptor 1/2, Jak1, and Tyk2 remained unchanged in ALD livers, whereas expression of IFN-␣, signal transducer and activator of transcription factor 1 (STAT1), and p48 were up-regulated and expression of STAT2 was down-regulated. I nterferon alfa (IFN-␣) therapy is the primary choice of treatment for viral hepatitis, a disease that affects millions of people worldwide. 1,2 IFN-␣ exerts an antiviral effect by modulating the immune system, including regulating antigen processing and presentation, and stimulating the development of specific T-helper-cell subsets. 3,4 In addition to modulation of the immune system, IFN directly eradicates the virus by stimulating production of endogenous antiviral proteins such as double-stranded RNA-activated protein kinase R (PKR), 2Ј-5Ј oligoadenylate synthetase (OAS), and MxA, a karyophilic 75 kd protein induced by IFN in mouse cells carrying the influenza virus resistance allele Mx ϩ through the Janus kinase (Jak)-signal transducer and activator of transcription factor (STAT) signaling cascade. 3,4 IFN-␣/ signaling begins with ligation and dimerization of the corresponding IFN-␣/ receptors (IFN␣R1 and IFN␣R2). Receptor dimerization induces autophosphorylation of the receptor-associated JAKs, Jak1 and Tyk2. These activated kinases also phosphorylate the receptor to recruit SH2 domain-containing STATs (STAT1 and STAT2) from the cytosol to the membrane to be phosphorylated. Once activated, STATs are released back into the cytosol for dimerization. Stat1:Stat2 heterodimers translocate into the nucleus, where they bind a third component, p48, forming the ISGF3 transcription factor complex that binds the interferonstimulated response element to initiate transcription of IFN-␣/-specific genes. 3,4 Several mechanisms have been implicated in down-regulation of IFN-␣/ signaling. Protein tyrosine phosphatases (PTPs) such as Shp-1, Shp-2, and CD45 phosphatase have been shown to dephosphorylate IFN␣R and JAKs, respectively. 5-8 A family of suppressors of cytokine signaling (SOCS) inhibitory proteins has been recently identified and shown to inhibit IFN signaling by targeting JAKs. 9 The JAK-STAT signaling pathway is also inhibited by activation of several kinases, including p42/44 MAP kinase, protein kinase C (PKC) and protein kinase A. [10][11][12][13] Although IFN-␣ has been used for the treatment of viral hepatitis for more than a decade, unfortunately, more than 60% to 70% of patients respond poorly. 14-16 Most patients experience